Medical Specialties > Structural Heart > TVT 2021 Clinical Presentation

 

12 SITES  |  N = 554 PATIENTS

 

The Early neo2 Registry is an investigator-initiated and conducted, single arm, multicenter registry that assessed the ACURATE neo2 Aortic Valve System’s performance.1

 
Echocardiographic images of 85% of the Early neo2 Registry patients were analyzed by an echocardiographic core-lab analysis and presented by Dr. Andreas Rück from the Karolinska Institute (Stockholm, Sweden) at TVT, 2021. View the presentation.2
 

 

 

The ACURATE neo2 Valve performed consistently for key patient outcomes:

 
Hemodynamic
Hemodynamic
Coronary Access
stroke icon
Complication Rates
Complication Rates
* Post-procedure echo. Core-Lab assessed site-reported; † In-Hospital; ‡ 30-Days; § Procedural
 

 

 

 

Percent of evaluable echocardiograms demonstrating post-procedure PVL rates from the core-lab adjudicated Early neo2 Registry.2

Active PVseal
 
 
Top